Physician profile
Sheena Boury
NPI 1366697393
$1,578.85
in general payments reported to CMS, 2019-2025
27 companies · $58.37 in 2025
The $58.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $137 · 2021: $282 · 2022: $130 · 2023: $208 · 2024: $75.98 · 2025: $58.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $391.07 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $203.64 | 2020-2024 | Vraylar, Qulipta |
| Novo Nordisk INC | $110.02 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $104.27 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.93 | 2021-2022 | |
| Astellas Pharma US INC | $59.48 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $58.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $52.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $48.25 | 2019-2020 | |
| Amarin Pharma, INC. | $42.41 | 2019-2021 | |
| Esperion Therapeutics, INC. | $42.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.15 | 2019-2022 | |
| Exact Sciences Corporation | $37.89 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $35.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.73 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $27.64 | 2019-2021 | |
| Smith+Nephew, INC. | $22.00 | 2020 | |
| Seqirus USA INC | $17.95 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Radius Health, INC. | $17.60 | 2019 | |
| Mdd US Operations, LLC | $15.04 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.48 | 2021 | |
| Allergan, INC. | $12.48 | 2020 | |
| Pulmonx Corporation | $12.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Boury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.